Looking ugly again today. Their achilles heel has been exposed - the impossibility of growing the business to an acceptable ROA.Rising costs and the inability to raise fees in the current environment will squeeze the profit margin even more.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025